Cocrystal Pharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
Item 14. Principal Accountant Fees and Services.
Audit Committee’s Pre-Approval Policies and Procedures
Our Audit Committee reviews and approves audit and permissible non-audit services performed by our independent registered public accounting firm (the “Principal Accountant”), as well as the fees charged for such services. In its review of non-audit service and its appointment of our independent registered public accounting firm, the Audit Committee considers and considered whether the provision of such services was compatible with maintaining independence. All of the services provided and fees charged by our Principal Accountant in 2024 and 2023 were approved by the Audit Committee in accordance with its pre-approval policy.
Principal Accountant Fees and Services
The following table shows the fees billed by our Principal Accountant for the years ended December 31, 2024 and 2023.
| 2024 ($) | 2023 ($) | |||
| Audit Fees (1) | 126,000 | 130,000 | ||
|---|---|---|---|---|
| Audit-Related Fees (2) | - | - | ||
| Total | 126,000 | 130,000 |
| (1) | Audit Fees relate to the audits of our annual financial statements and the review of our interim quarterly financial statements. |
| (2) | Audit-Related fees relate to the assessment of our internal controls. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.